Cadrenal Therapeutics (CVKD)

• Market cap: $9.94M
• 1 day: -14.83%
• 5 days: -29.52%
• 1 month: -50.52%
• 3 months: -35.8%
• 6 months: -69.27%
• Year to date: -42.02%
• 1 year: -75.89%
• 5 years: -93.12%
• 10 years: -93.12%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4